Enhanced Wound Healing for Diabetics

促进糖尿病患者的伤口愈合

• 批准号: 6484343
• 负责人: JEFFREY A GREENSPAN
• 金额: $ 46.94万
• 依托单位: MUNIN CORPORATION
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6484343
• 关键词: angiogenesis; antiserum; biomarker; collagen; diabetes mellitus; drug screening /evaluation; growth factor; immediate early protein; laboratory mouse; nonhuman therapy evaluation; protein purification; recombinant proteins; skin; topical drug application; wound healing

Description (provided by applicant): Impaired and delayed wound healing are significant problems in diabetics. Furthermore, aging and diabetes together further compound the problem. These observations have created interest in pharmacologic enhancement of healing with growth factors involved in the body?s wound repair process. Clinical trials have been discouraging, with only modest improvement in wound repair in humans. Studies indicate that cells in healing-impaired individuals may fail to respond adequately to growth factors. Thus, wound healing in such individuals may not be improved by growth factor treatment, but may require administration of downstream factors normally induced in cells in response to growth factors involved in healing, but not induced in cells of those with poor wound healing capability. In Phase I of this proposal, a particular factor that is strongly implicated as a critical component of wound healing in the body, and whose expression is normally induced by growth factors, will be tested for its ability to enhance wound healing in diabetic mice. If successful, this factor will be developed in Phase II as a clinical wound-healing agent, particularly for those with impaired wound healing, such as diabetics. PROPOSED COMMERCIAL APPLICATION: Wound treatment costs total billions of dollars (almost $10 billion for pressure ulcers alone). Impaired and delayed wound healing affect more than a half million individuals annually and are significant problems in diabetics (over 15 million diabetics are in the U.S.) and the elderly. Impaired/delayed healing also has severe impact on ischemia that leads to heart attacks (the leading cause of mortality) and limb amputations.

描述（由申请人提供）：伤口愈合受损和延迟是糖尿病患者面临的重大问题。此外，衰老和糖尿病一起使问题进一步复杂化。这些观察结果引起了人们对利用参与人体伤口修复过程的生长因子促进愈合的药理作用产生了兴趣。临床试验令人沮丧，人类伤口修复的改善程度有限。研究表明，愈合受损个体的细胞可能无法对生长因子做出充分反应。因此，这些个体的伤口愈合可能无法通过生长因子治疗得到改善，但可能需要施用通常在细胞中响应参与愈合的生长因子诱导的下游因子，但在伤口愈合能力差的那些人的细胞中不诱导。在该提案的第一阶段，将测试一种与体内伤口愈合的关键成分密切相关的特定因子，其表达通常由生长因子诱导，将测试其增强糖尿病小鼠伤口愈合的能力。如果成功，该因子将在第二阶段开发作为临床伤口愈合剂，特别是对于那些患有损伤的人 伤口愈合，例如糖尿病患者。 拟议的商业应用：伤口治疗费用总计数十亿美元（仅压疮就花费近 100 亿美元）。伤口愈合受损和延迟每年影响超过 50 万人，并且是糖尿病患者（美国有超过 1500 万糖尿病患者）和老年人的重大问题。 愈合受损/延迟也会对缺血产生严重影响，从而导致心脏病发作（死亡的主要原因）和截肢。